The prognostic significance of COX-2 and survivin expression in ovarian cancer

Pathology Research and Practice

Volumn 204, Issue 4, 2008, Pages 241-249

  Athanassiadou, Pauline ^a   Grapsa, Dimitra ^a   Athanassiades, Peter ^b   Gonidi, Maria ^a   Athanassiadou, Anna Maria ^a   Tsipis, Angelos ^b   Patsouris, Efstratios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ALEXANDRA HOSPITAL   (Greece)

Author keywords

COX 2; Immunocytochemistry; Ovarian cancer; Prognosis; Survivin

Indexed keywords

CYCLOOXYGENASE 2; SURVIVIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; OVARY CARCINOMA; POSTMENOPAUSE; PREMENOPAUSE; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE;

EID: 40749156590     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2007.11.004     Document Type: Article

References (75)

1. Aihara T., Munakata S., Morino H., and Takatsuka Y. Touch imprint cytology and immunohistochemistry for the assessment of sentinel lymph nodes in patients with breast cancer. Eur. J. Surg. Oncol. 29 (2003) 845-848
2. Aihara T., Munakata S., Morino H., and Takatsuka Y. Comparison of frozen section and touch imprint cytology for evaluation of sentinel lymph node metastasis in breast cancer. Ann. Surg. Oncol. 11 (2004) 747-750
3. Ali-Fehmi R., Che M., Khalifeh I., Malone J.M., Morris R., Lawrence W.D., and Munkarah A.R. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma. Cancer 98 (2003) 1423-1429
4. Ambrosini G., Adida C., and Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3 (1997) 917-921
5. Bantis A., Giannopoulos A., Gonidi M., Liossi A., Aggelonidou E., Petrakakou E., Athanassiades P., and Athanassiadou P. Expression of p120, Ki-67 and PCNA as proliferation biomarkers in imprint smears of prostate carcinoma and their prognostic value. Cytopathology 15 (2004) 25-31
6. Barnes M.N., Chhieng D.F., Dreher M., Jones L., Talley L., and Partridge E.E. Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: initial examination of celecoxib as a chemopreventive agent. Gynecol. Oncol. 98 (2005) 376-382
7. Brinton L.A., Moghissi K.S., Scoccia B., Westhoff C.L., and Lamb E.J. Ovulation induction and cancer risk. Fertil. Steril. 83 (2005) 261-274
8. Chen G., Wilson R., McKillop J.H., and Walker J.J. The role of cytokines in the production of prostacyclin and thromboxane in human mononuclear cells. Immunol. Invest. 23 (1994) 269-279
9. Cohen C., Lohmann C.M., Cotsonis G., and Lawson D. Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. Mod. Pathol. 16 (2003) 574-583
10. Cramer D.W., Harlow B.L., Titus-Ernstoff L., Bohlke K., Welch W.R., and Greenberg E.R. Over the counter analgesics and risk of ovarian cancer. Lancet 351 (1998) 104-107
11. Creager A.J., Geisinger K.R., Perrier N.D., Shen P., Shaw J.A., Young P.R., Case D., and Levine E.A. Intraoperative imprint cytologic evaluation of sentinel lymph nodes for lobular carcinoma of the breast. Ann. Surg. 239 (2004) 61-66
12. Cserni G. Effect of increasing the surface sampled by imprint cytology on the intraoperative assessment of axillary sentinel lymph nodes in breast cancer patients. Am. Surg. 69 (2003) 419-423
13. Daponte A., Guidozi F., Tiltman A.J., Marineanu A., and Taylor L. p53 as a prognostic factor for stage III serous adenocarcinoma of the ovary. Anticancer Res. 19 (1999) 2387-2389
14. Denkert C., Kobel M., Pest S., Koch I., Berger S., Scwabe M., Siegert A., Reles A., Klosterhalfen B., and Hauptmann S. Expression of cyclooxygenase-2 is an independent prognostic factor in human ovarian carcinoma. Am. J. Pathol. 160 (2002) 893-903
15. Dore M., Cote L.C., Mitchell A., and Sirois J. Expression of prostaglandin G/H synthase type 1, but not type 2, in human ovarian adenocarcinomas. J. Histochem. Cytochem. 46 (1998) 77-84
16. DuBois R.N., Awad J., Morrow J., Roberts II L.J., and Bishop P.R. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-alpha and phorbol ester. J. Clin. Invest. 93 (1994) 493-498
17. Dutta T., Sharma H., Kumar L., Dinda A.K., Kumar S., Bhatla N., and Singh N. Neoadjuvant chemotherapy for epithelial ovarian cancer-role of apoptosis. Cancer Chemother. Pharmacol. 56 (2005) 427-435
18. Erkinheimo T.L., Lassus H., Finne P., van Rees B.P., Leminen A., Ylikorkala O., Haglund C., Butzow R., and Ristimaki A. Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of Her-2/neu and poor outcome in serous ovarian carcinoma. Clin. Cancer Res. 10 (2004) 538-545
19. Ferrandina G., Legge F., Martinelli E., Ranelletti F.O., Zannoni G.F., Lauriola L., Gessi M., Gallotta V., and Scambia G. Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br. J. Cancer 92 (2005) 271-277
20. Ferrandina G., Ranelletti F.O., Lauriola L., Fanfani F., Legge F., Mottolese M., Nicotra M.R., Natali P.G., Zakut K.H., and Scambia G. Cyclooxygenase-2 (COX-2), epidermal growth-factor receptor (EGFR) and Her-2/neu expression in ovarian cancer. Gynecol. Oncol. 85 (2002) 305-310
21. FIGO (International Federation of Gynecology and Obstetrics). Annual report on the results of treatment in gynecological cancer. Int. J. Gynaecol. Obstet. 83 Suppl. 1 (2003) 1-229
22. Flens M.J., van der Valk P., Tadema T.M., Huysmans A.C., Risse E.K., van Tol G.A., and Meijer C.J. The contribution of immunocytochemistry in diagnostic cytology. Comparison and evaluation with immunohistology. Cancer 65 (1990) 2704-2711
23. Gallo O., Franchi A., Magnelli L., Sardi I., Vannacci A., Boddi V., Chiarugi V., and Masini E. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 3 (2001) 53-61
24. Greene D.R., Taylor S.R., Wheeler T.M., and Scardino P.T. DNA ploidy by image analysis of individual foci of prostate cancer: a preliminary report. Cancer Res. 51 (1991) 4084-4089
25. Harris R.E., Beebe-Donk J., Doss H., and Burr Doss D. Aspirin, ibuprofen and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol. Rep. 13 (2005) 559-583
26. Hsu S.M., Raine L., and Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem. 29 (1981) 577-580
27. Huang M., Stolina M., Sharma S., Mao J.T., Zhu L., Miller P.W., Wollman J., Herschman H., and Dubinett S.M. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res. 58 (1998) 1208-1216
28. Ito T., Shiraki K., Sugimoto K., Yamanaka T., Fujikawa K., Ito M., Takase K., Moriyama M., Kawano H., Hayashida M., Nakano T., and Suzuki A. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 31 (2000) 1080-1085
29. Kawasaki H., Altieri D.C., Lu C.D., Toyoda M., Tenjo T., and Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates of colorectal cancer. Cancer Res. 58 (1998) 5071-5074
30. Khalifeh I., Munkarah A.R., Lonardo F., Malone J.M., Morris R., Lawrence W.D., and Ali-Fehmi R. Expression of Cox-2, CD34, Bcl-2 and p53 and survival in patients with primary peritoneal serous carcinoma and primary serous carcinoma. Int. J. Gynecol. Pathol. 23 (2004) 162-169
31. Khuri F.R., Wu H., Lee J.J., Kemp B.L., Lotan R., Lippman S.M., Feng L., Hong W.K., and Xu X.C. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin. Cancer Res. 7 (2001) 861-867
32. Klevesath M.B., Godwin R.J., Bannon R., Munthali L., and Coveney E. Touch imprint cytology of core needle biopsy specimens: a useful method for immediate reporting of symptomatic breast lesions. Eur. J. Surg. Oncol. 31 (2005) 490-494
33. Klimp A.H., Hollema H., Kempinga C., van der Zee A.G., de Vries E.G., and Daemen T. Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res. 61 (2001) 7305-7309
34. Koss L.G., and Melamed M.R. Recognizing and classifying cells. In: Koss L.G., and Melamed M.R. (Eds). Koss' Diagnostic Cytology. fifth ed. (2006), Lippincot Williams and Wilkins, Philadelphia 119-120
35. Krysan K., Dalwadi H., Sharma S., Pold M., and Dubinett S. Cyclooxygenase-2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Res. 64 (2004) 6359-6362
36. Krysan K., Merchant F.H., Zhu L., Dohadwala M., Luo J., Lin Y., Heuze-Vourc'h N., Pold M., Seligson D., Chia D., Goodglick L., Wang H., Strieter R., Sharma S., and Dubinett S. COX-2 dependent stabilization of survivin in non-small cell lung cancer. FASEB J. 18 (2004) 206-208
37. Li M., Qi S.Y., Wang Y., Feng S.X., Zhang B.Z., and Wang R. Expression and clinical significance of vascular endothelial growth factor, cyclooxygenase-2 and Bcl-2 in borderline ovarian tumors. Arch. Gynecol. Obstet. 272 (2005) 48-52
38. Lin J., Hsiao P.W., Chiu T.H., and Chao J.I. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells. Biochem. Pharmacol. 70 (2005) 658-667
39. Ma X., Wang S., Zhou J., Xing H., Xu G., Wang B., Chen G., Lu Y.P., and Ma D. Induction of apoptosis in human ovarian epithelial cancer cells by antisurvivin oligonucleotides. Oncol. Rep. 14 (2005) 275-279
40. Mano Y., Kikuchi Y., Yamamoto K., Kita T., Hirata J., Tode T., Ishii K., and Nagata I. Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. Eur. J. Cancer 35 (1999) 1214-1219
41. Matsumoto Y., Ishiko O., Deguchi M., Nakagawa E., and Ogita S. Cyclooxygenase-2 expression in normal ovaries and epithelial ovarian neoplasms. Int. J. Mol. Med. 8 (2001) 31-36
42. Monzo M., Rosell R., Felip E., Astudillo J., Sanchez J.J., Maestre J., Martin C., Font A., Barnadas A., and Abad A. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J. Clin. Oncol. 17 (1999) 2100-2104
43. Munkarah A., and Ali-Fehmi R. COX-2: a protein with an active role in gynecological cancers. Curr. Opin. Obstet. Gynecol. 17 (2005) 49-53
44. Munkarah A.R., Genhai Z., Morris R., Baker V.V., Deppe G., Diamond M.P., and Saed G.M. Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor NS398 in epithelial ovarian cancer cells. Gynecol. Oncol. 88 (2003) 429-433
45. O'Banion M.K., Winn V.D., and Young D.A. cDNA cloning and functional activity of a glycocorticoid-regulated inflammatory cyclooxygenase. Proc. Natl. Acad. Sci. USA 89 (1992) 4888-4892
46. Ozzello L., DeRosa C., Habif D.V., and Greene G.L. An immunohistochemical evaluation of progesterone receptor in frozen sections, paraffin sections, and cytologic imprints of breast carcinomas. Cancer 67 (1991) 455-462
47. Pennati M., Campbell A.J., Curto M., Binda M., Cheng Y., Wang L.Z., Curtin N., Golding B.T., Griffin R.J., Hardcastle I.R., Henderson A., Zaffaroni N., and Newell D.R. Potential use of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down regulation. Mol. Cancer Ther. 4 (2005) 1328-1337
48. Qui L., Di W., Jiang O., Scheffler E., Derby S., Yang J., Kouttab N., Wanebo H., Yan B., and Wan Y. Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death. Int. J. Oncol. 27 (2005) 1441-1448
49. Raspollini M.R., Amunni G., Villanucci A., Boddi V., Baroni G., Taddei A., and Taddei G.L. Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome. Gynecol. Oncol. 92 (2004) 806-812
50. Raspollini M.R., Amunni G., Villanucci A., Boddi V., and Taddei G.L. Increased cyclooxygenase-2 (COX-2) expression and P-glycoprotein-170 (MDR1) expression is associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with high and low survival. Int. J. Gynecol. Cancer 15 (2005) 255-260
51. Richardon G.S., Scully R.E., Nikrui N., and Nelson Jr. J.H. Common epithelial cancer of the ovary (2). N. Engl. J. Med. 312 (1985) 474-483
52. Rosenberg L., Palmer J.R., Rao R.S., Coogan P.F., Strom B.L., Zauber A.G., Stolley P.D., and Shapiro S. A case-control study of analgesic use and ovarian cancer. Cancer Epidemiol. Biomarker Prev. 9 (2000) 933-937
53. Sakamoto A., Yokoyama Y., Umemoto M., Futagami M., Sakamoto T., Bing X., and Mizunuma H. Clinical implication of expression of cyclooxygenase-2 and peroxisome proliferators activated-receptor gamma in epithelial ovarian tumors. Br. J. Cancer 91 (2004) 633-638
54. Sakuma K., Fujimori T., Hirabayashi K., and Terano A. Cyclooxygenase(COX)-2 immunoreactivity and relationship to p53 and Ki-67 expression in colorectal cancer. J. Gastoenterol. 34 (1999) 189-194
55. Sarela A.I., Macadam R.C., Farmery S.M., Markham A.F., and Guillou P.J. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46 (2000) 645-650
56. Sasaki M., Morimoti K., Koh M., Wakasa K., Haba T., and Kinoshita H. Cytologic diagnosis of estrogen and progesterone receptors in breast imprints. Acta Cytol. 46 (2002) 1056-1060
57. Seo S.S., Song Y.S., Kang D.H., Park I.A., Bang Y.J., Kang S.B., and Lee H.P. Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer. Gynecol. Oncol. 92 (2004) 927-935
58. Sheng H., Shao J., Morrow J.D., Beauchamp D., and DuBois R.N. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 58 (1998) 362-366
59. Shigemasa K., Tian X., Gu L., Shiroyama Y., Nagai N., and Ohama K. Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas. Int. J. Oncol. 22 (2003) 99-105
60. Shirahama T., Arima J., Akiba S., and Sakakura C. Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer 92 (2001) 188-193
61. Subbaramaiah K., Altorki N., Chung W.J., Mestre J.R., Sampat A., and Dannenberg A.J. Inhibition of cyclooxygenase-2 gene expression by p53. J. Biol. Chem. 274 (1999) 10911-10915
62. Sui L., Dong Y., Ohno M., Watanabe Y., Sugimoto K., and Tokuda M. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int. J. Oncol. 21 (2002) 315-320
63. Surowiak P., Materna V., Denkert C., Kaplenko I., Spaczynski M., Dietel M., Zabel M., and Lage H. Significance of cyclooxygenase 2 and MDR1/P-glycoprotein coexpression in ovarian cancers. Cancer Lett. 235 (2006) 272-280
64. Symowicz J., Adley B.P., Woo M.M., Auersperg N., Hudson L.G., and Stack M.S. Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells. Cancer Res. 65 (2005) 2234-2242
65. Tanaka K., Iwamoto S., Gon G., Nohara T., Iwamoto M., and Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin. Cancer Res. 6 (2000) 127-134
66. Takai N., Miyazaki T., Nishida M., Nasu K., and Miyakawa I. Expression of survivin is associated with malignant potential in epithelial ovarian carcinoma. Int. J. Mol. Med. 10 (2002) 211-216
67. Tiniakos D.G., Robinson K.B., Greenwood H., Cullen P., Cook A.I., Horne C.H., and Angus B. C-erb B-2 and p53 expression in breast cancer fine needle aspirates. Cytopathology 7 (1996) 178-186
68. Tringler B., Lehner R., Shroyer A.L., and Shroyer K.R. Immunohistochemical localization of survivin in serous tumors of the ovary. Appl. Immunohistochem. Mol. Morphol. 12 (2004) 40-43
69. Tsujii M., and DuBois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83 (1995) 493-501
70. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., and DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93 (1998) 705-716
71. Vane J. Towards a better aspirin. Nature 567 (1994) 215-216
72. Wang Z., Xie Y., and Wang H. Changes in survivin messenger RNA level during chemotherapy treatment in ovarian cancer cells. Cancer Biol. Ther. 4 (2005) 716-719
73. Werner M., Chott A., Fabiano A., and Battifora H. Effect of formalin fixation and processing on immunohistochemistry. Am. J. Surg. Pathol. 24 (2000) 1016-1019
74. Yoshida H., Ishiko O., Sumi T., Matsumoto Y., and Ogita S. Survivin, bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell- and serous-type ovarian carcinomas. Int. J. Oncol. 19 (2001) 537-542
75. Zaffaroni N., Pennati M., Colella G., Perego P., Supino R., Gatti L., Pilotti S., Zunino F., and Daidone M.G. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol. Life Sci. 59 (2002) 1406-1412